The B7-H4 Targeting Therapies Market stands as an innovative domain within immuno-oncology, delivering novel pathways for cancer intervention that extend beyond traditional checkpoint blockade strategies. B7-H4, also identified as B7S1 or VTCN1 (V-set domain containing T cell activation inhibitor 1), serves as an immune checkpoint protein that has emerged as a promising therapeutic...